ライフサイエンスコーパス: serotonin

1 experiments with 5-hydroxy-L-tryptophan and serotonin.

2 , an enzyme associated with the synthesis of serotonin.

3 synthesizes the vast majority of the body's serotonin.

4 brain neuromodulators, such as oxytocin and serotonin.

5 ased on immunostainings against synapsin and serotonin.

6 e of serotonin, which in turn impacts on the serotonin 1A receptor system, by modulating its availabi

7 cohort also underwent (11)C-WAY100635 scans (serotonin-1A receptor [5-HT1A]), we examined whether usi

8 Mice with manipulation of serotonin 1B receptor (5-HT1BR) expression were included

9 ned and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preferen

10 weight gain were blunted in mice lacking the serotonin 2C receptor (HTR2C).

11 Here we show that serotonin 5-HT1B receptors in cholecystokinin (CCK) inhi

12 The serotonin 5-HT2B receptor has been involved in various b

13 Here, we show that activation of serotonin 5-HT2C receptors, which engage Erk1/2 pathway

14 fied in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approac

15 Serotonin 5-HT4 receptors are promising candidates in IB

16 Serotonin 5-HT6 receptor has been proposed as a promisin

17 ing preclinical evidence has implicated both serotonin (5-HT) 2C and 2A receptors as potential mechan

18 g laying-defective and contain low levels of serotonin (5-HT) and high levels of the 5-HT metabolite

19 Caenorhabditis elegans, the biogenic amines serotonin (5-HT) and octopamine regulate a number of foo

20 sour sensing cells, Type III cells, release serotonin (5-HT) in response to the presence of sour (ac

21 is regulated by chemical signaling, of which serotonin (5-HT) is a key transmitter.

22 Serotonin (5-HT) is associated with mood and motivation

23 STATEMENT The modulation of the amygdala by serotonin (5-HT) is important for emotional regulation a

24 Release of serotonin (5-HT) is thought to have an important role in

25 at Necdin deletion disturbs the migration of serotonin (5-HT) neuronal precursors, leading to altered

26 Serotonin (5-HT) neurons project from the raphe nuclei t

27 taining monoamines such as dopamine (DA) and serotonin (5-HT) occur in the periventricular zones of t

28 A dopaminergic marker (TH), serotonin (5-HT) or GABA do not co-localize with Galphat

29 ine (OA) receptor, OCTR-1, and a 5-HT1A-like serotonin (5-HT) receptor, SER-4, that involves a comple

30 The serotonin (5-HT) system and the amygdala are key regulat

31 ated SERT Ala56 variant have altered central serotonin (5-HT) system function, as well as elevated pe

32 encoding the integrin beta3 subunit with the serotonin (5-HT) system, likely via its modulation of th

33 stigated a widely distributed CNS modulator, serotonin (5-HT), for its ability to modulate the biophy

34 brainstem modulated by the neurotransmitter serotonin (5-HT).

35 These compounds include selective serotonin (5-HT)2C receptor antagonists, a 5-HT4 recepto

36 drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these me

37 Serotonin (5-hydroxytryptamine, 5-HT) and brain-derived

38 deaths are associated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the

39 Serotonin (5-hydroxytryptamine, 5-HT) is a well-known ne

40 The serotonin (5-hydroxytryptamine, 5-HT) system modulates m

41 rain atlas into a protein density map of the serotonin (5-hydroxytryptamine, 5-HT) system.

42 thelium is the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an impor

43 Here, we show that serotonin (5HT), which is known to regulate gamma power,

44 aviors were accompanied by striatal dopamine/serotonin abnormalities and cortical excitation-inhibiti

45 e, gamma-aminobutyric acid (GABA), dopamine, serotonin, acetylcholine and opioids-and numerous ion ch

46 ne at spinal alpha2 -adrenoceptors, although serotonin, acting on facilitatory spinal 5-HT3 receptors

47 However, mechanisms by which central serotonin action leads to fat loss remain unknown.

48 Although much is known about how serotonin acts on its cellular targets, how serotonin re

49 a U.S. Food and Drug Administration-approved serotonin agonist (lorcaserin) to septic rats greatly im

50 before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (T

51 xon terminals to allow optimal allocation of serotonin among target neurons.

52 Serotonin, an important neuromodulator in the brain, is

53 n, and stable T3R3 hexamers loaded with both serotonin and arginine were obtained.

54 rthermore, by comparing the cue responses of serotonin and dopamine neurons, we found differences in

55 r accumulation of neurotransmitters, such as serotonin and dopamine, in insulin storage granules in p

56 l transduction, G protein coupled receptors, serotonin and glycosaminoglycan metabolisms among others

57 Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have in

58 Opioid, serotonin and NMDA mechanisms acting in rostral ventrome

59 rainstem neurons that release the monoamines serotonin and noradrenaline, and local vessel dilation i

60 ly prescribed antidepressant, is a selective serotonin and norepinephrine reuptake inhibitor in human

61 T and a higher selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil

62 TRIs), which elevate dopamine in addition to serotonin and norepinephrine, may demonstrate greater ef

63 nvestigated the roles of the biogenic amines serotonin and octopamine in regulating locomotion behavi

64 ght both a specific function in learning for serotonin and the importance of studying its role across

65 rethral neuroendocrine cells expressing both serotonin and YFP, whereas single serotonin labeling was

66 yap1, and receptors for substance P, orexin, serotonin, and ATP.

67 easurements of neurotransmitters (melatonin, serotonin, and epinephrine) at various concentrations fo

68 monoaminergic systems, notably dopamine and serotonin, and integrates cognitive with emotional and s

69 t, with one exception, monoamines (dopamine, serotonin, and norepinephrine) signal via metabotropic r

70 p control are GABA, dopamine, acetylcholine, serotonin, and several neuropeptides.

71 the monoamine neurotransmitters dopamine and serotonin, and suffer a multi-systemic disorder characte

72 In contrast, vasopressin, serotonin, and testosterone play only limited roles.

73 hemical double labeling studies with YFP and serotonin antisera combined with electron microscopy wer

74 Biogenic amines, such as like serotonin, are conserved neurotransmitters that regulate

75 This study identifies serotonin as a new critical neural substrate for GLP-1 i

76 ons of neurons using acetylcholine, GABA, or serotonin as neurotransmitters.

77 d plasma with disruptions also in tryptophan/serotonin, bile acid and lipid metabolism.

78 Both methods indicated serotonin binding on the hexamer surface (site III) as w

79 ependently converged on the observation that serotonin binds well within the insulin hexamer (site I)

80 that not all immunoreactive neurons produce serotonin, but have the capability for serotonin uptake.

81 This suggests that serotonin can modulate the ability to learn via a mechan

82 We show that three gastrointestinal signals-serotonin, CCK, and PYY-are necessary or sufficient for

83 tide in proportion to fluctuations in neural serotonin circuit functions, and its release is regulate

84 Extracellular dopamine and serotonin concentrations are determined by the presynapt

85 ) dams had decreased mammary gland and serum serotonin concentrations compared to controls.

86 es a significant contribution to circulating serotonin concentrations during lactation, with no effec

87 WAP-Cre x Lrp5 (FL/FL) dams had elevated serotonin concentrations in both the mammary gland and c

88 mmary-derived serotonin to circulating serum serotonin concentrations was previously unknown.

89 Comparisons with the patterns of serotonin-containing neurons in major tetraconate taxa s

90 ansporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively).

91 ing genetic diseases leading to dopamine and serotonin deficiency.

92 th additional neurotransmitter (dopamine and serotonin) deficiency.

93 Serotonin depletion impaired the ability of exendin-4, a

94 nticipate that investigation of dopamine and serotonin disturbances will be facilitated by measuremen

95 Monoamine neurotransmitters such as serotonin, dopamine, histamine, and noradrenaline have i

96 synthesized, and evaluated as ligands of 34 serotonin, dopamine, histamine, melatonin, acetylcholine

97 leus norepinephrine (LC-NE) and dorsal raphe serotonin (DR 5-HT) systems.

98 hich exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities

99 dentifies a simple computational function of serotonin for state-dependent sensory processing, depend

100 ts latent effects of early life adversity on serotonin function may play a role in this phenomenon.

101 While serotonin has been linked to value-based decision-making

102 The modulation by serotonin has qualitative similarities with that for a d

103 shifts in vasculature, amino acid transport, serotonin homeostasis, and mitochondrial function.

104 ed neurons, the "contralaterally projecting, serotonin-immunoreactive deutocerebral neurons" (CSDns),

105 the morphology of individually identifiable serotonin-immunoreactive neurons in the ventral nerve co

106 raconata contains a comparably low number of serotonin-immunoreactive neurons, facilitating individua

107 The involvement of serotonin in aggression has traditionally been attribute

108 g rates that could explain the importance of serotonin in inhibiting perseverative responding.

109 zed mechanosensor, the EC cell releases this serotonin in response to mechanical forces.

110 he biosynthesis and turnover of dopamine and serotonin in the brain.

111 we depict the interplay between oxytocin and serotonin in the nonhuman primate brain.

112 physiological or pathophysiological roles of serotonin in tissues where 5-HT2 receptors are co-expres

113 basal neuronal excitability, which occludes serotonin-induced enhanced excitability.

114 Serotonin inhibits the cholinergic rhythm, and increases

115 f TPH2 immunoreactivity and largely preserve serotonin innervation of motor neurons in the spinal cor

116 e investigated mechanisms by which GLP-1 and serotonin interact at the level of the central nervous s

117 reduce body weight in rats, suggesting that serotonin is a critical mediator of the energy balance i

118 Serotonin is a homeostatic regulator of the mammary glan

119 r, chronic exposure to excessive circulating serotonin is considered one of the most important contri

120 Serotonin is implicated in mood and affective disorders.

121 reat the many psychiatric disorders in which serotonin is implicated.

122 The bioamine serotonin is required for food-dependent induction of bu

123 n the awake macaque the modulatory effect of serotonin is surprisingly uniform: it causes a mainly mu

124 ssing both serotonin and YFP, whereas single serotonin labeling was observed in 36% and exclusive YFP

125 xamine effects on blood, placenta and embryo serotonin levels and neurodevelopment at embryonic day E

126 The mechanisms that control extracellular serotonin levels in vivo are not well-defined.

127 ly reduced concentrations of brain dopamine, serotonin levels were markedly diminished, and this pert

128 We found that serotonin mainly decreased the gain of the visual respon

129 Mammary-derived serotonin makes a significant contribution to circulatin

130 1b, which encodes an enzyme that synthesizes serotonin, mark a subpopulation of fibroblast-like cells

131 ered in neuropathy and the effects of excess serotonin may now become inhibitory through activation o

132 hly stable, selective, and sensitive ambient serotonin measurements in vitro.

133 :Nth1 complex structure with those of 14-3-3:serotonin N-acetyltransferase and 14-3-3:heat shock prot

134 Moreover, serotonin neither systematically changes the selectivity

135 tory neuropeptides fail to properly modulate serotonin neurons and the behavior they mediate.

136 vide direct evidence for a role of brainstem serotonin neurons in spasticity.

137 Optogenetic stimulation of serotonin neurons in the dorsal raphe causes mice to mov

138 INTERPRETATION: Degeneration of serotonin neurons is necessary to trigger spasticity thr

139 r findings show how the activity patterns of serotonin neurons support a role in cognitive flexibilit

140 In the nematode C. elegans, serotonin neurons that drive female reproductive behavio

141 ant SOD1 expression selectively in brainstem serotonin neurons was sufficient to rescue loss of TPH2

142 n mice to study a population of dorsal raphe serotonin neurons, whose activity we could link to norma

143 d increase the electrical activity of the DR serotonin neurons.

144 logical effects of peptidergic inhibition on serotonin neurons.

145 lities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation.

146 gamma-aminobutyric acid (GABA), dopamine and serotonin neurotransmitter systems.

147 gastrointestinal pain and painful FGIDs and serotonin noradrenergic reuptake inhibitors can also be

148 t associated with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine.

149 l prescriptions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor between conc

150 orded selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor prescription

151 from selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 s

152 y ill selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor users, but u

153 Serotonin-norepinephrine reuptake inhibitors (SNRIs) sig

154 ctive serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), an

155 ive serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs], tr

156 Serotonin-norepinephrine reuptake inhibitors also appear

157 Selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors are among t

158 se of selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors previously

159 tient selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors were contin

160 We examined the role of serotonin on well-defined tuning properties (orientation

161 ity, and suggest a revised model of dopamine-serotonin opponency with potential clinical implications

162 Serotonin or 5-hydroxytryptamine (5-HT) has been shown t

163 activities, and low binding competition with serotonin or other orthosteric ligands.

164 utive maternal prescriptions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor

165 eurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxyntomodulin (enteroglucag

166 Glucagon-like peptide 1 (GLP-1) and serotonin play critical roles in energy balance regulati

167 umulation of dopamine precursor levodopa and serotonin precursor 5-hydroxytryptophan.

168 Dorsal raphe (DR) harbors cell bodies of serotonin-producing neurons that supply serotonin to the

169 Amputation stimulates serotonin production in regenerating fin fibroblasts, ye

170 ypes: alpha7-nAChR, alpha4beta2-nAChR, and a serotonin receptor (5-HT3AR), along with a fluorescent r

171 tophan hydroxylase 1 (Tph1, rs262731280) and serotonin receptor 3A (Htr3a, rs50670893) were associate

172 l structure of LSD in complex with the human serotonin receptor 5-HT2B.

173 ase inhibitor) and pergolide (a dopamine and serotonin receptor agonist) robustly reduced alcohol int

174 y was used to advance the novel concept that serotonin receptor subtype 5-HT2C contributes critically

175 nputs from the basolateral nucleus (BLA) and serotonin receptor subtype 5-HT2CR in the BLA, but not C

176 The serotonin receptor subtypes 2 comprise 5-HT2A, 5-HT2B, a

177 The ionotropic serotonin receptor, 5-HT3 , is expressed by many develop

178 We demonstrate that clemizole binds to serotonin receptors and its antiepileptic activity can b

179 imaging-based human brain atlas of important serotonin receptors and the transporter.

180 rtex of Phf8 deficient mice and identify the serotonin receptors Htr1a and Htr2a as direct targets of

181 roxytryptamine (5-HT) 2A (5-HT2A) and 5-HT2C serotonin receptors in the hypothalamus were altered by

182 previously that pharmacologic activation of serotonin receptors on motor neurons increases motor neu

183 RETATION: Our findings suggest activation of serotonin receptors with lorcaserin may provide the firs

184 d agonists for members of the 5-HT2 class of serotonin receptors, 2,5-dimethoxy-4-iodoamphetamine (DO

185 The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal st

186 cular explanation for LSD's actions at human serotonin receptors.

187 ics in offspring of mothers with deficits in serotonin related pathways during stressful pregnancies.

188 ockdown decreases mechanosensitive currents, serotonin release and downstream physiological effects.

189 A total of 11 patients (8.1%) had positive serotonin release assay and 80 patients had positive ant

190 parin enzyme-linked immunosorbent assay, and serotonin release assay scores.

191 eparin enzyme-linked immunosorbent assay and serotonin release assay testing between January 1, 2011,

192 Positive serotonin release assay was noted in nine of 11 patients

193 4/heparin enzyme-linked immunosorbent assay, serotonin release assay, and Warkentin 4Ts scores.

194 serotonin acts on its cellular targets, how serotonin release is regulated in vivo remains poorly un

195 waning of serum-induced heparin-independent serotonin release) with successful outpatient rivaroxaba

196 factor 4 [PF4]/heparin immunoassay, positive serotonin-release assay).

197 oamine-releaser with particularly pronounced serotonin- releasing properties, has unique subjective e

198 n into 5-hydroxytryptophan (the precursor of serotonin), respectively.

199 ntidepressants that are strong inhibitors of serotonin reuptake actually increase the risk for ICH an

200 of antidepressants with strong inhibition of serotonin reuptake are associated with an increased risk

201 sant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all

202 Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has

203 after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

204 we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram) are stud

205 benzodiazepine, and 293 were treated with a serotonin reuptake inhibitor during pregnancy.

206 In contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced im

207 Maternal treatment with a serotonin reuptake inhibitor is also associated with hyp

208 Maternal serotonin reuptake inhibitor use was associated with hyp

209 ion was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortene

210 For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remai

211 The selective serotonin reuptake inhibitor, paroxetine, was previously

212 reatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces excessive grooming

213 excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepinephrine re

214 Selective serotonin reuptake inhibitor/serotonin-norepinephrine re

215 case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine re

216 dies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepinephrine re

217 as generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepinephrine re

218 exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepinephrine re

219 In contrast, the use of selective serotonin reuptake inhibitors (aHR for MOF, 1.43; 95% CI

220 ors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the tricyclic

221 Selective serotonin reuptake inhibitors (SSRIs) are the most commo

222 Selective serotonin reuptake inhibitors (SSRIs) may increase the r

223 Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) significantly redu

224 he relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepin

225 nitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).

226 Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serotonin-norep

227 inhibitors, patients taking higher doses of serotonin reuptake inhibitors and who had a longer durat

228 ce continues to support the use of selective serotonin reuptake inhibitors as first-line pharmacologi

229 ponded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertralin

230 gether with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsess

231 The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unkn

232 setron) either in combination with selective serotonin reuptake inhibitors or as monotherapy in the t

233 behavioral therapy with or without selective serotonin reuptake inhibitors remains a preferred initia

234 Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because onl

235 year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use of mood st

236 of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use of mood st

237 Compared with patients who were not taking serotonin reuptake inhibitors, patients taking higher do

238 used to examine the effect of treatment with serotonin reuptake inhibitors, with or without antipsych

239 ared with TCAs and strong compared with weak serotonin reuptake inhibitors.

240 disorder, GAD, or use of benzodiazepines or serotonin reuptake inhibitors.

241 itivity, and response to long-term selective serotonin reuptake inhibitors.

242 eory linked to the strength of inhibition of serotonin reuptake of an antidepressant.

243 -current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depres

244 itor, the other from paroxetine, a selective serotonin-reuptake inhibitor.

245 er insights into the mechanisms that control serotonin's extracellular levels.

246 d adsorption voltammetry (FSCAV), to measure serotonin's steady-state, extracellular chemistry.

247 rs, are electrically excitable, and modulate serotonin-sensitive primary afferent nerve fibers via sy

248 rmined by the presynaptic dopamine (DAT) and serotonin (SERT) transporters, respectively.

249 The symporters for the biogenic amines serotonin (SERT), dopamine (DAT), and norepinephrine (NE

250 rmacologically verify the selectivity of the serotonin signal.

251 activity can be mimicked by drugs acting on serotonin signalling pathways e.g. trazodone and lorcase

252 We further observe misregulation of serotonin signalling within the prefrontal cortex of Phf

253 sh a direct link between Phf8 expression and serotonin signalling, identifying this histone demethyla

254 stent with low basal occupancy by endogenous serotonin.SIGNIFICANCE STATEMENT We here show that combi

255 auopathy, while loss of no other dopamine or serotonin synthesis genes tested had this effect.

256 function in other genes in the dopamine and serotonin synthesis pathways did not alter tau-induced t

257 e data provide unparalleled insight into the serotonin system of the human brain.

258 Dopamine, serotonin, the neuropeptide receptor NPR-1, and the TGF-

259 For global modulators such as serotonin, the use of distinct neuroendocrine peptides f

260 The contribution of mammary-derived serotonin to circulating serum serotonin concentrations

261 s of serotonin-producing neurons that supply serotonin to the hypothalamic nuclei.

262 imaging with a radiotracer specific for the serotonin transporter (5-HTT), (11)C-McN5652, we found t

263 ermined X-ray crystal structure of the human serotonin transporter (hSERT).

264 lthio)benzylamine ((11)C-HOMADAM) imaging of serotonin transporter (SERT) density in healthy control

265 obesity, potentially attributed to a reduced serotonin transporter (SERT) function.

266 t years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided

267 oimaging, and genetic findings implicate the serotonin transporter (SERT) in autism spectrum disorder

268 Serotonin transporter (SERT) is a transmembrane transpor

269 Reduced expression of the serotonin transporter (SERT) promotes anxiety and cocain

270 n, (123)I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented

271 The serotonin transporter (SERT/SLC6A4) has a rich pharmacol

272 norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission

273 18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the 5-HT1AR, respectively.

274 ative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant

275 May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporte

276 ding, VMAT2 binding, (18)F-FDOPA uptake, and serotonin transporter binding in multiple brain regions

277 Serotonin transporter binding in the cortex did not diff

278 rkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compa

279 manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem

280 ng PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutat

281 46)- which directs reduced expression of the serotonin transporter gene (5-HTT).

282 entifying two common genetic variants of the serotonin transporter gene and their association with in

283 The serotonin transporter gene has previously been implicate

284 igates whether a genetic polymorphism of the serotonin transporter gene moderates susceptibility to a

285 methylation of the proximal promoter of the serotonin transporter gene, which predicts greater incre

286 ol) carried at least one short allele of the serotonin transporter gene.

287 When infant genotype for serotonin transporter polymorphism was taken into accoun

288 and 145 control) was genotyped for a common serotonin transporter polymorphism.

289 hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is associated with

290 was no association between genotypes of the serotonin transporter promoter region polymorphism and s

291 Using immunostaining for the serotonin transporter, SERT, we describe the complete pa

292 f the maternal polymorphism, 5HTTLPR, in the serotonin transporter, SLC6A4, coupled with prenatal str

293 rmalin-induced pain, as did mice lacking the serotonin transporter.

294 Serotonin turnover and expression of 5-hydroxytryptamine

295 oduce serotonin, but have the capability for serotonin uptake.

296 gonist quinpirole, but not norepinephrine or serotonin, was prevented by the GABAA receptor antagonis

297 GWamide, DLamide, FLamide, FVamide, MIP, and serotonin were present in fewer cells in demarcated regi

298 found that oxytocin provokes the release of serotonin, which in turn impacts on the serotonin 1A rec

299 e the oxidation and recovery of dopamine and serotonin, while transmission spectrum measurement was c

300 itters-gamma-aminobutyric acid, dopamine and serotonin-with high spectroscopic confidence in the mous